Sugi Predict

Sugi Predict / Compounds / SCHEMBL17501039

SCHEMBL17501039

SCHEMBL17501039

Cc1nnc(-c2cc(N3CCOC[C@H]3C)nc3c(-c4ccn[nH]4)nccc23)o1

nearest known ligand 0.79

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ ATR Q13535 20/20 0.79
▸ ATRIP Q8WXE1 20/20 0.79
▸ GAK O14976 1/20 0.71
▸ CYP3A4 P08684 1/20 0.71
▸ CYP2C8 P10632 1/20 0.71
▸ CYP2C9 P11712 1/20 0.71
▸ PIK3CB P42338 1/20 0.71
▸ MTOR P42345 1/20 0.71
▸ PRKDC P78527 1/20 0.71
▸ ATM Q13315 1/20 0.71
▸ RIOK2 Q9BVS4 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17501562 0.88 ATR (1.00) ATRATRIPGAKCYP3A4CYP2C8
SCHEMBL17527654 0.88 ATR (1.00) ATRATRIPGAKCYP3A4CYP2C8
SCHEMBL30140401 0.88 ATR (1.00) ATRATRIPGAKCYP3A4CYP2C8
SCHEMBL17527680 0.84 ATR (1.00) ATRATRIP
SCHEMBL29395585 0.84 ATR (1.00) ATRATRIP
SCHEMBL20081788 0.84 ATR (1.00) ATRATRIP
SCHEMBL18110016 0.84 ATR (1.00) ATRATRIP
SCHEMBL18110015 0.84 ATR (1.00) ATRATRIP
SCHEMBL17527650 0.84 ATR (1.00) ATRATRIP
SCHEMBL17527537 0.84 ATR (1.00) ATRATRIP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210128723-A1 COMBINATION OF ATR KINASE INHIBITORS AND PD-1/PD-L1 INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2021-05-06 — — US claimed
EP-3177619-B1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES Bayer Pharma AG (DE) 2018-04-25 — — EP claimed
US-20170216304-A1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-08-03 — — US claimed
US-9549932-B2 2-(morpholin-4-yl)-1,7-naphthyridines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-01-24 — — US claimed
US-20160287604-A1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-10-06 — — US claimed
US-20230346927-A1 COMBINATION of ATR KINASE INHIBITORS and PD-1/PD-L1 INHIBITORS BAYER AKTIENGESELLSCHAFT (DE) 2023-11-02 — — US disclosed
US-11690911-B2 Combination of ATR kinase inhibitors and PD-1/PD-L1 inhibitors BAYER AKTIENGESELLSCHAFT (DE) 2023-07-04 — — US disclosed
US-11529356-B2 2-(morpholin-4-yl)-1,7-naphthyridines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2022-12-20 — — US disclosed
CN-110204544-B 2- (morpholin-4-yl) -1, 7-naphthyridine 拜耳制药股份公司 2022-04-12 — — CN disclosed
CN-110256427-B 2- (morpholin-4-yl) -1, 7-naphthyridine 拜耳制药股份公司 2022-02-22 — — CN disclosed
EP-3395818-B1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES Bayer Pharma AG (DE) 2021-09-22 — — EP disclosed
US-20200383991-A1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-12-10 — — US disclosed
US-20180256591-A1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-09-13 — — US disclosed
US-9993484-B2 2-(morpholin-4-yl)-1,7-naphthyridines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-06-12 — — US disclosed
EP-3177619-B1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES Bayer Pharma AG (DE) 2018-04-25 — — EP disclosed
US-20170216304-A1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-08-03 — — US disclosed
EP-3177619-A1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES Bayer Pharma Aktiengesellschaft (DE) 2017-06-14 — — EP disclosed
US-9549932-B2 2-(morpholin-4-yl)-1,7-naphthyridines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-01-24 — — US disclosed
US-20160287604-A1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-10-06 — — US disclosed
WO-2016020320-A1 2-(MORPHOLIN-4-YL)-L,7-NAPHTHYRIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-02-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11690911-B2 Combination of ATR kinase inhibitors and PD-1/PD-L1 inhibitors ATR, PDCD1, CHEK1 ATR 1/4885ATRIP 7/4885GAK 174/4885
US-20180256591-A1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES POLQ, CCND2, NRAS ATR 3508/4885ATRIP 1927/4885GAK 620/4885
US-11529356-B2 2-(morpholin-4-yl)-1,7-naphthyridines POLQ, CCND2, NRAS ATR 3508/4885ATRIP 1927/4885GAK 620/4885
US-20210128723-A1 COMBINATION OF ATR KINASE INHIBITORS AND PD-1/PD-L1 INHIBITORS ATR, PDCD1, CHEK1 ATR 1/4885ATRIP 7/4885GAK 156/4885
US-20170216304-A1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES POLQ, CCND2, NRAS ATR 3508/4885ATRIP 1927/4885GAK 620/4885
US-20230346927-A1 COMBINATION of ATR KINASE INHIBITORS and PD-1/PD-L1 INHIBITORS ATR, PDCD1, CHEK1 ATR 1/4885ATRIP 7/4885GAK 165/4885
US-20200383991-A1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES POLQ, CCND2, NRAS ATR 3508/4885ATRIP 1927/4885GAK 620/4885
US-20160287604-A1 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES POLQ, CCND2, NRAS ATR 3508/4885ATRIP 1927/4885GAK 620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback